Remarks at 2025 U.S. Treasury Market Conference, Federal Reserve Bank of New York, New York City As prepared for delivery ...

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive ...

Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session -- -- Two posters on ...

In this Q&A, Beowolff Capital CEO Andrew Wolff explains why he believes the future of the art market lies in transparency, data and A.I.-powered collaboration. He outlines how integrating ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

Business and legislative leaders gathered on November 10 in Lexington for the Kentucky Chamber’s 2026 Legislative Preview ...

Even established businesses with substantial IT budgets make critical backup mistakes that can cost millions in lost data and ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...

Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

"Public and private markets are converging, but the data infrastructure hasn't kept pace," said Nicholas Fusco, CEO of PM Insights. "We're not just aggregating data; we're revealing the economic ...

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib. Read ...